Showing 3881-3890 of 9152 results for "".
- New Analysis Ranks Tremfya Highest Among PsA Treatments for Skin Clearancehttps://practicaldermatology.com/news/new-analysis-ranks-tremfya-highest-among-psa-treatments-for-skin-clearance/2461054/Tremfya® (guselkumab) ranks highest for skin clearance, based on Psoriasis (PsO) Area Severity Index (PASI) 90 response, among 23 psoriatic arthritis (PsA) treatment regimens, results of a newly reported Network Meta-Analysis (NMA) show. In terms of joint inflammation
- Nevisense Boosts Clinician Confidence in Early Melanoma Diagnosishttps://practicaldermatology.com/news/nevisense-boosts-clinicians-confidence-in-early-melanoma-diagnosis/2461053/Nevisense provides valuable diagnostic guidance for clinicans when evaluating atypical pigmented skin lesions, according to a new study. The Nevisense method uses small electrical impulses to detect cellular irregularities beneath the skin’s surface. In the pilot study,
- Survey Reveals Impact of AGA on Affected Men, Interest in New Therapieshttps://practicaldermatology.com/news/survey-reveals-impact-of-aga-on-affected-men-interest-in-new-therapies/2461046/Nearly two-thirds (64%) of men with androgentic alopecia (AGA) say the condition has a negative affect on their lives, yet more than half (56%) have never sought treatment for the condition, results of a survey show. Findings from the survey, conducted on behalf of
- Scientis: Mikki Bey Crawford Named US VP and General Manager, Aesthetic Dermatologyhttps://practicaldermatology.com/news/scientis-mikki-bey-crawford-named-us-vp-and-general-manager-aesthetic-dermatology/2461045/Mikki Bey Crawford is now US Vice President and General Manager, Aesthetic Dermatology for Scientis. In her new role, she will lead the sales and marketing teams to accelerate the growth of Cyspera® in the US. "We are so pleased t
- Phase 3 Data Show Benefit of Dupixent to Reduce Itch in Prurigo Nodularishttps://practicaldermatology.com/news/phase-3-data-show-benefit-of-dupixent-to-reduce-itch-in-prurigo-nodularis/2461044/Dupixent® (dupilumab) from Sanofi and Regeneron significantly reduced itch and skin lesions compared to placebo at 24 weeks in a phase 3 trial in adults with uncontrolled prurigo nodularis. The new data confirm positive results
- Is CBG the Next CBD for Skincare?https://practicaldermatology.com/news/is-cbg-the-next-cbd-for-skincare/2461042/Cannabigerol (CBG) shows antioxidant, anti-inflammatory, and skin health-boosting activity in lab assays and provides similar benefits when applied topically to human skin, according to new research. In a single-blind c
- The National Eczema Association and Pediatric Dermatology Research Alliance Receive Collaborative Engagement Award from PCORIhttps://practicaldermatology.com/news/the-national-eczema-association-and-pediatric-dermatology-research-alliance-receive-collaborative-engagement-award-from-pcori/2461041/The
- Lubriderm Launches Skin Scholarship with the National Hispanic Health Foundationhttps://practicaldermatology.com/news/lubriderm-launches-skin-scholarship-with-the-national-hispanic-health-foundation/2461030/Lubriderm is partnering with the
- Case Study Highlights Possible Role for Minimal Dose Radiotherapy in Severe Acne Keloidalis Nuchaehttps://practicaldermatology.com/news/case-study-highlights-possible-role-for-minimal-dose-radiotherapy-in-severe-acne-keloidalis-nuchae/2461021/Minimal dose radiotherapy may offer new hope for severe acne keloidalis nuchae (AKN), according to research in the Journal of the American Academy of Dermatology Case Reports. The study found t
- FDA Accepts Arcutis Biotherapeutics’ NDA for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-arcutis-biotherapeutics-nda-for-roflumilast-cream-for-adults-and-adolescents-with-plaque-psoriasis/2461018/The FDA accepted Arcutis Biotherapeutics’ new drug application (NDA) for roflumilast cream for the treatment of psoriasis in adults and adolescents. The FDA assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2022. “With the FDA c